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The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma
(mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-
RelatedSymptomsQuestionnaire,andtheEQ-5Dinstrument.HRQoLwasevaluatedoverallandbyhealthstatein120mSTS/mBS
patientsenrolledintheSABINEstudyacrossninecountriesinEuropeandNorthAmerica.Utilitywasestimatedfromresponsesto
the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample
with little variation across health states. However, patients with progressive disease reported a clinically signiﬁcant lower utility
(0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated
with reduced HRQoL and utility among patients with metastatic disease.
1.Introduction
Sarcomas are rare cancers of connective tissue, such as
bone, muscle, nerves, fatty tissue, and cartilage. Sarcomas
fall into three broad categories, soft tissue (STS), primary
bone cancers, and gastrointestinal stromal tumors (GISTs);
there are, however, many subtypes of sarcoma within these
categories. The incidence of STS in the US is 2.4 to 3.6 per
100,000 inhabitants per year depending on age and race, and
the incidence in Europe is 3.2 per 100,000 per year [1, 2].
39% of patients have advanced disease (deﬁned as regional
or metastatic) at their initial diagnosis, whereof 15% present
with metastatic disease [1]. Among those presenting with
localized disease, approximately 35% of patients progress to
metastatic disease [3]. Treatment with chemotherapy is the
standard route of care in patients with mSTS and mBS [4, 5].
The most common form of bone sarcoma, osteosarcoma
and Ewing’s sarcoma, the second most common form of2 Sarcoma
bone sarcoma, are cancers that most commonly aﬀect
adolescents [6]. Malignant ﬁbrous histiocytoma (MFH),
a former classiﬁcation dismantled among diﬀerent sub-
types, including leiomyosarcomas, myxoﬁbrosarcomas, and
liposarcoma are most commonly aﬀecting middle-aged or
elderly individuals. The most common sarcoma types are
leiomyosarcoma representing approximately 20% of total
STScases,MFH(19%),andliposarcoma(10%)contributing
to approximately 50% of cases [7]. Other types of STS
subtypes include synovial sarcoma (approximately 2.7%
of total STS cases), ﬁbrosarcoma (6.7%), Kaposi sarcoma
(12%), dermatoﬁbrosarcoma (8%), and sarcoma not other-
wise speciﬁed (12%).
In order to assess the impact of a new medical treat-
ment on resource allocation, one needs a measure that
incorporates both survival and quality of life. A quality-
adjusted life year (QALY) is a generic outcome measure
that is constructed by weighting the length of time spent
in diﬀerent disease states by a utility value (on a scale of 0
to 1, where 0 represents dead and 1 best imaginable health)
corresponding to the quality of life associated with the level
of health status [8].
Utility weights can be estimated with the EQ-5D which
is a standardized, non-disease-speciﬁc instrument for use as
a measure of health outcomes. With the EQ-5D instrument,
patients can rate health states which are then converted into
utilities using a scoring algorithm. Such scoring algorithms
have been developed based on the preferences of the general
population [9]. Furthermore, there are also cancer-speciﬁc
quality of life elicitation methods. One commonly employed
questionnaire is the EORTC QLQ-C30 questionnaire which
is developed to assess quality of life in cancer patients by
assessing patient’s overall quality of life, functionality, and
disease symptoms [10].
There is limited published literature on HRQoL in
metastatic sarcoma patients. Poveda and colleagues (2005)
used the EORTC QLQ-C30 in 23 patients with metastatic
sarcoma, by administering the instrument before and after
treatment with pegylated liposomal doxorubicin [11]. Qual-
ity of life did not seem to worsen during therapy. Systematic
literature review indicated that there are no published utility
values collected in patients with metastatic sarcoma.
A primary objective of the sarcoma treatment and
burden of illness in North America and Europe (SABINE)
study was to describe utility weights in metastatic sarcoma
patients who have attained a complete response (CR), partial
response (PR), or stable disease (SD) following chemother-
apy. The three HRQoL instruments used were the EQ-
5D, the EORTC QLQ-C30, and the 3-item Cancer-Related
Symptoms Questionnaire (originally used in SUCCEED trial
[12], a phase III clinical trial among advanced sarcoma
patients). Secondary objectives were to explore quality of life
according to predeﬁned health states and to identify factors
that predict quality of life.
2. Methods
The present study was a cross-sectional patient survey where
data on quality of life in patients with metastatic soft tissue
Table 1: Predeﬁned health states.
Health state Deﬁnition
1 1st-line chemotherapy, preprogressive disease
2 2nd-line chemotherapy, preprogressive disease
3 3rd-line or higher chemotherapy, preprogressive
disease
4 Progressive disease (on or oﬀ chemotherapy)
5 After chemotherapy, pre progressive disease
sarcoma (mSTS) and metastatic bone sarcoma (mBS) were
collected. Eligible patients were recruited consecutively (the
reason being not to inﬂuence patient selection) by their
treating physician at a total of 25 study sites across nine
countries:Canada,USA,Germany,France,Italy,TheNether-
lands, Spain, UK, and Sweden. The study was approved by
theethicalcommitteesineachrespectivecountryandpatient
informed consent was obtained.
Patients included were 18 years of age or older, had
a conﬁrmed diagnosis of metastatic soft tissue or bone
sarcoma and had had a favourable response (CR, PR, or SD)
according to the WHO or RECIST 1.0 criteria after any line
of chemotherapy. The following soft tissue subtypes were
included: leiomyosarcoma, liposarcoma, and undiﬀerenti-
ated pleomorphic sarcoma/malignant ﬁbrous histiocytoma,
and the following bone sarcoma subtypes were included:
osteosarcoma and Ewing’s sarcoma. These subtypes were
selected to reduce the heterogeneity in the patient sample.
Patients enrolled in the SUCCEED trial were excluded as
this study was intended to evaluate health-related quality
of life in sarcoma patients as they are being treated in
actual clinical practice, and to avoid interference with the
SUCCEED clinical trial. Patients were enrolled in the patient
survey between December 2009 and March 2011.
Patients were recruited according to predeﬁned sarcoma-
related health states related to the patient’s line of treatment
andresponsestatus.Amaximumofﬁvepatientspersitewere
allowed to be enrolled in each health state. The predeﬁned
health states are presented in Table 1.O ﬀ-chemotherapy was
deﬁned as being longer than six weeks since last dose of
chemotherapy given the persistence of toxicity (e.g., fatigue
and mucositis) following completion of a chemotherapy
regimen.
The physician or study nurse answered a short question-
naire with demographic and treatment and disease-related
questions. Three health-related quality of life elicitation
questionnaires: European Quality of Life Questionnaire
(EQ-5D), EORTC QLQ-C30, and a 3-item Cancer-Related
Symptoms Questionnaire (used in the SUCCEED clinical
trial) were administered to the patients at the physician visit
at one single point in time.
The EQ-5D self-assessment questionnaire provides two
analysis variables: EQ-5D visual analog scale (VAS) and EQ-
5D descriptive system. For both VAS and utility, a higher
score indicates better health, and the questions address the
patient’s health status on the day of questionnaire comple-
tion. Patients with missing data on the EQ-5D questionnaireSarcoma 3
were excluded from the utility calculations. EQ VAS is a
visual analogue scale that ranges from 0 (worst imaginable
health state) to 100 (best imaginable health state). The
EQ-5D descriptive system deﬁnes health in terms of ﬁve
dimensions: mobility, self-care, usual activities, pain or
discomfort, and anxiety or depression. Each dimension
is divided into three levels that correspond to whether
the respondent has (1) no problem, (2) some problem,
or (3) extreme problems thus consisting of 243 possible
combinations. To each combination of answers, a utility
value, anchored at 0 (death) and 1 (full health) is assigned.
However,therearehealthstatesconsideredworsethandeath,
which is why negative utility values may occur. The utility
value is in turn based on a set of preference weights (tariﬀ)
elicited from general population samples by some other
method, for example, the time trade-oﬀ (TTO) method. The
tariﬀ used in this study were EQ-5D value weights based on
a TTO study from a UK population [9], with a sensitivity
analysis using a tariﬀ from a US population [13].
The EORTC QLQ-C30 questionnaire includes 30 items
of which 28 have four response levels (not at all, a little, quite
a bit, and very much). The remaining two items are rated on
a scale from 0 (very poor) to 7 (excellent). The instrument is
composed of both multiitem scalesand single-item measures
including ﬁve functional scales (physical, role, emotional,
cognitive, and social functioning), nine symptomatic scales,
and a global health status scale representing the quality of
life. 25 items are based on recall period of seven days. The
ﬁve items that physical functioning is composed of have no
explicit recall period. In this study, missing values were not
imputed as missing values appeared nonrandom.
The 3-item Cancer-Related Symptoms Questionnaire
consists of three questions to describe the existence and
severity (mild, moderate, or severe) of three symptoms;
pain, cough, and shortness of breath. This questionnaire was
developed for and subsequently used in the SUCCEED trial
[12].
Clinically relevant diﬀerences were assessed in quality
of life between diﬀerent health states using the EORTC
QLQ-C30 HRQoL and utility values. For EORTC QLQ-C30
variables which range from 0 to 100, the clinically relevant
diﬀerences were determined as a “little change” (5–10 points
change in the score), a “moderate change” (10–120 points),
and “very much change” (>20 points) [14]. For EQ-5D
utilities,whichrangefrom −0.59to1,aminimallyimportant
diﬀerence is 0.074 units [15].
The parameters estimated from the EORTC QLQ-C30,
the 3-item Cancer-Related Symptoms Questionnaire and
the utility values were calculated as means along with their
respective standard deviations. An analysis of covariance
regression analysis (ANCOVA) [16] was done to assess
predictors of quality of life with the EORTC QLQ-C30 global
health status score as dependent variable. The following
covariates were included in the full model.
Demographic variables:
(i) age at survey completion (continuous variable),
(ii) gender,
(iii) region (categorical variables: North America: North-
ern Europe, Southern Europe):
(a) Northern Europe is deﬁned as Sweden, Nether-
lands, UK, and Germany,
(b) Southern Europe is deﬁned as France, Italy, and
Spain.
Disease-speciﬁc variables:
(i) health state (categorical variable, 1–5 as speciﬁed
previously in Table 1),
(ii) pain (categorical variable, as measured by the symp-
toms questionnaire),
(iii) cough (categorical variable, as measured by the
symptoms questionnaire),
(iv) shortness of breath (categorical variable, as measured
by the symptoms questionnaire),
(v) number of metastases (continuous variable),
(vi) time since diagnosis (continuous variable).
The ANCOVA regression was initially run including all
independent variables listed above (i.e., the full model).
Then, statistically insigniﬁcant covariates were manually
removed using backward selection criteria and the model
was rerun until all covariates were signiﬁcant at a 5%
level. The ﬁnal model speciﬁcation was also checked for
heteroskedasticity and normality of residuals.
Statistical signiﬁcance was evaluated at the 5% level. All
P-values reported are two-sided.
AnalyseswereperformedusingSAS9.2.Allanalyseswere
exploratory. The reported P-values should be considered
only for informative purposes and not for drawing any
deﬁnitive conclusions.
3. Results
3.1. Patient Characteristics. Of the 120 sarcoma patients
enrolled into the study, 99 were mSTS patients and 21 had
mBS. Four of the 120 patients were considered not valid for
ﬁnal study analysis due to the following reasons: missing
response status (n = 1), did not complete any patient
questionnaire (n = 1), enrolled in SUCCEED clinical trial
(n = 1), and was too young (16.9 years old at survey
completion) (n = 1). The evaluable patient set was therefore
116 sarcoma patients.
Table 2 shows the demographic and disease characteris-
tics of the patients. Of the 116 evaluable patients, 96 (82.8%)
patients had mSTS and 20 (17.2%) had mBS. 68 (58.6%)
patients were female. The mean age at metastatic sarcoma
diagnosis was 49.5 years (SD = 17.1), with a range of 16.1 to
83.8 years. Extremity (35.3%) followed by retroperitoneum
(16.4%) were the most frequently reported site of disease.
Note that patients could have more than one metastasis. The
mean number of sites of metastases per patient reported
was 1.4. The most common site of metastasis was the lung
(44.6%). Other sites of metastases were bone, lymph nodes,
pleura, abdomen, retroperitoneum, pancreas, mediastinum,4 Sarcoma
Table 2: Patient characteristics.
N = 116 (100%)
Gender, N (%)
Female 68 (58.6%)
Histology, N (%)
Soft tissue sarcoma 96 (82.8%)
Leiomyosarcoma 38 (32.8%)
Liposarcoma 23 (19.8%)
Synovial sarcoma 14 (12.1%)
Undiﬀerentiated pleomorphic sarcoma/malignant ﬁbrous histiocytoma 21 (18.1%)
Bone sarcoma 20 (17.2%)
Osteosarcoma 8 (6.9%)
Ewing’s sarcoma 12 (10.3%)
Site, N( %)
Extremity 41 (35.3%)
Retroperitoneum 19 (16.4%)
Superﬁcial trunk and chest wall 5 (4.3%)
Head and neck 2 (1.7%)
Cutaneous 1 (0.9%)
Visceral non-GI 12 (10.3%)
Visceral GI 2 (1.7%)
Knee 1 (0.9%)
Hip 0
Shoulder 1 (0.9%)
Pelvis 4 (3.5%)
Femur/humerus 2 (1.8%)
Ribs 0
Other 24 (20.7%)
Missing 2 (1.7%)
Site of metastases, N (%)
CNS 1 (0.6%)
Lung 74 (44.6%)
Liver 24 (14.5%)
Soft tissue 11 (6.6%)
Locoregional 28 (16.9%)
Other 25 (15.1%)
Missing 3 (1.8%)
Receiving chemotherapy, N (%)
Yes 73 (62.9%)
Number of sites of metastases
Mean (SD) 1.4 (0.7)
Minimum, maximum 1, 3
Age at sarcoma diagnosis
Mean (SD) 47.7 (17.2)
Minimum, maximum 13.6, 83.7
Age at metastatic disease diagnosis
Mean (SD) 49.5 (17.1)
Minimum, maximum 16.1, 83.8
Age at attainment of current response status
Mean (SD) 51.6 (17)
Minimum, maximum 18.5, 84.3Sarcoma 5
skeletal, kidney, pelvis, and skull. The majority of patients
(62.9%) were receiving chemotherapy at the time of ques-
tionnaire completion.
3.2. Health Utilities. The EQ-5D utility values are given in
Table 3. The mean utility score was 0.69 for the pooled
patient sample. Patients with mBS (0.68) and patients with
mSTS (0.69) had a similar mean utility score, and the
diﬀerence between the EQ-5D utility scores for mSTS and
mBS patients was not statistically signiﬁcant (P = 0.93).
The mean VAS score (range 0–100) was reported to be
65 for the pooled patient sample, 65.8 for mSTS patients
and 61.3 for mBS patients. The observed diﬀerence was not
statistically signiﬁcant (P = 0.52).
In addition, EQ-5D utility values by health state (HS)
for the pooled patient sample, using the UK weights, are
presented in Table 4. Patients on 1st-line chemotherapy had
an average utility score of 0.72, while the results for 2nd and
3rd line or higher were 0.64 and 0.77, respectively. Results
were similar for patients oﬀ chemotherapy, preprogression
(0.77). Patients with progressive disease reported a lower
mean utility (0.56). VAS scores were also calculated by health
state.Incontrasttotheresultsbyhealthstateusingutilityval-
ues, the VAS scores decline with increasing lines of therapy.
The nonparametric Mann-Whitney test was used to
assess any potential statistically signiﬁcant diﬀerences in
median utility values between the following health states
(HS):HS1(median =0.76)versusHS2(median =0.73);HS1
versus HS3 (median = 0.75); HS2 versus HS3; HS4 (median
= 0.66) versus HS5 (median = 0.76). The median utility
was calculated for each respective comparative group. These
comparisons were selected because they were deemed as
clinically meaningful comparisons. A statistically signiﬁcant
diﬀerence was found between HS4, progressive disease, and
HS5, oﬀ-chemotherapy pre-progression, (P = 0.003). There
were no other statistically signiﬁcant diﬀerences between the
compared health states.
A sensitivity analysis was also performed using the US
EQ-5Dtariﬀ.Thisresultedinameanutilityvalueof0.76(SD
= 0.18) for the pooled patient sample and hence a diﬀerence
in mean utility of 0.075 compared to the UK-based utility
(mean = 0.69, SD = 0.26). This is mainly due to the UK tariﬀ
yielding negative values, while there were none for the US
tariﬀ based utilities as well as a higher median value for the
UStariﬀutilities.Theanalysisforutilityvaluesbyhealthstate
was therefore rerun. The conclusions of the utility by health
state analysis using the US-based tariﬀ remained the same
(data not shown).
3.3. Quality of Life. Q o La sm e a s u r e db yt h eE O R T CQ L Q -
C30 global health status variable indicated a similar mean
quality of life score in the mBS subsample (63.3) and
the mSTS subgroup (62.0). These results are presented in
Table 5. In addition, the EORTC QLQ-C30 functional scale
(range 0–100) was scored for the patient’s physical, role,
emotional, cognitive, and social functioning. The lowest
score (indicating poorer quality of life) was reported for role
37.9%
69%
56%
33.6%
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20.7%
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Figure 1: Cancer-related symptoms based on the 3-item question-
naire, all patients.
functioning (mean 60.6, SD = 33.6) and social functioning
(mean 65.9, SD = 29.1).
For the EORTC QLQ-C30 symptoms scale (range 0–
100),whereahighervalueindicatesmoresymptoms,scoring
was performed for the common cancer-related side eﬀects
fatigue, nausea and vomiting, pain, dyspnoea, insomnia,
appetite loss, constipation, diarrhoea, and ﬁnancial prob-
lems. The highest symptoms scale scores were reported for
the fatigue score (mean 40.1, SD = 28.4) followed by insom-
nia (mean 28.9, SD = 29.9) and pain (mean 27.6, SD = 27.2).
The results were consistent in both mSTS and mBS patients.
Figure 1 presents results from the 3-item Cancer-Related
Symptoms Questionnaire for the pooled patient sample. The
majority of patients had none to mild pain; however, 20.7%
of patients reported moderate pain. 69% of patients had
no cough, and the majority of patients had no shortness of
breath (56%). Results were consistent across the mSTS and
mBS subsamples.
3.4. Clinically Relevant Diﬀerences in Quality of Life and
Utility. Table 6 shows the mean EQ-5D utility diﬀerence
between health states (HS), and whether there is a mini-
mal clinically relevant diﬀerence. The results indicate that
patients on 1st-line chemotherapy (HS 1, N = 17, mean =
0.72) had a clinically relevant higher utility than patients on
2nd-line treatment (HS 2, N = 22, mean = 0.64). There was
no clinically relevant diﬀerence in utility between patients on
1st-line (HS 1) and patients on 3rd-line treatment (HS 3;
N = 12, mean = 0.77). Furthermore, patients on 2nd line
treatment have clinically relevant lower utility than patients
on 3rd line treatment. Comparing patients in progressive
disease (HS 4, N = 28, mean = 0.56) against patients with
stable disease that are oﬀ chemotherapy treatment (HS 5,
N = 36, mean = 0.77) result in a clinically relevant lower
utility for patients with progressive disease.
The analysis was repeated for the EORTC QLQ-C30
instrument. These results are presented in Table 6 below. In
line with the results of the EQ-5D utility values, there is
a decline in quality of life with patients on later lines of
chemotherapy treatment. The change is small but clinically6 Sarcoma
Table 3: QoL based on the EQ-5D.
Statistic All (N = 116) mSTS (N = 96) mBS (N = 20)
Mobility N (%)
No problems 64 (55.2%) 52 (54.2%) 12 (60%)
Some problems 48 (41.4%) 40 (41.7%) 8 (40%)
Conﬁned to bed 4 (3.5%) 4 (4.2%) 0
Missing 0 0 0
Self-care N (%)
No problems 95 (81.9%) 75 (78.1%) 20 (100%)
Some problems 20 (17.2%) 20 (20.8%) 0
Unable to wash or dress myself 0 0 0
Missing 1 (0.9%) 1 (1%) 0
Usual activities N (%)
No problems 48 (41.4%) 43 (44.8%) 5 (25%)
Some problems 60 (51.7%) 46 (47.9%) 14 (70%)
Unable to perform usual activities 7 (6%) 6 (6.3%) 1 (5%)
Missing 1 (0.9%) 1 (1%) 0
Pain/discomfort N (%)
No pain/discomfort 44 (37.9%) 38 (39.6%) 6 (30%)
Moderate pain/discomfort 66 (56.9%) 54 (56.3%) 12 (60%)
Extreme pain/discomfort 6 (5.2%) 4 (4.2%) 2 (10%)
Missing 0 0 0
Anxiety/depression N (%)
Not anxious/depressed 64 (55.2%) 53 (55.2%) 11 (55%)
Moderately anxious/depressed 49 (42.2%) 41 (42.7%) 8 (40%)
Extremely anxious/depressed 3 (2.6%) 2 (2.1%) 1 (5%)
Missing 0 0 0
Utility score1 N 114 94 20
Mean (SD) 0.69 (0.26) 0.69 (0.26) 0.68 (0.27)
Median 0.73 0.73 0.74
Min, max −0.08, 1 −0.08, 1 −0.08, 1
95% CI 0.64, 0.73 0.64, 0.74 0.55, 0.8
VAS score2 N 116 96 20
Mean (SD) 64.97 (20.14) 65.75 (19.63) 61.25 (22.63)
Median 70 70 65
Min, max 0, 100 0, 100 15, 90
95% CI 61.27, 68.68 61.77, 69.73 50.66, 71.84
Note: mSTS: metastatic soft tissue sarcoma, mBS: metastatic bone sarcoma; 1range −0.59 (worse than death)—1 (full health); 2range 0 (worst imaginable
health)—100 (best imaginable health).
relevant, described in the table as “little change”, in quality
of life between patients on 1st-(HS 1) and 2nd-(HS 2)
line chemotherapy treatment. The change is also clinically
relevant between patients on 1st-(HS 1) and patients on
3rd-(HS 3) line of chemotherapy treatment. But the change
is not clinically relevant between patients on 2nd-(HS 2)
and 3rd-(HS 3) line chemotherapy treatment. These results
thus suggest that there is a clinically relevant change in
quality of life between 1st-line treatment and 2nd/3rd-line
treatment.For patients with progressive disease (HS4), there
was large decrease in quality of life compared to patients oﬀ
chemotherapy with stable disease (HS 5).
3.5. Determinants of Quality of Life . The regression model
showed that the patient’s health state (HS) and number of
sites of metastases were statistically signiﬁcant predictors of
quality-of-life, as measured by the EORTC QLQ-C30 global
health status score. Results are displayed in Table 7.T h e
health state parameter estimate shows that, compared to
patients in HS 5 (favourable response and oﬀ chemother-
apy), patients in HS 1 (favourable response and on 1st-
line chemotherapy) had an estimated −9 . 5d e c r e a s eo nt h e
EORTC QLQ-C30 quality of life scale. However, this eﬀect
is not statistically signiﬁcant (P = 0.14). Patients in HS 2
and HS 3 (favourable response and on 2nd- and 3rd-lineSarcoma 7
Table 4: EQ-5D utility values and VAS scores by health state.
Statistic EQ-5D utility1 VAS score2
Health state 1 N 17 17
1st-line chemotherapy
Mean (SD) 0.72 (0.31) 68.82 (14.44)
Median 0.76 70
Min, max −0.08, 1 30, 85
95% CI 0.56, 0.88 61.4, 76.25
Health state 2 N 22 23
2nd-line chemotherapy
Mean (SD) 0.64 (0.33) 65.04 (18.91)
Median 0.73 70
Min, max −0.08, 1 15, 85
95% CI 0.49, 0.78 56.86, 73.22
Health state 3 N 12 12
3rd-line chemotherapy
Mean (SD) 0.77 (0.14) 63.75 (17.9)
Median 0.75 64
Min, max 0.59, 1 40, 90
95% CI 0.68, 0.86 52.38, 75.12
Health state 4 N 28 28
Progressive disease
Mean (SD) 0.56 (0.27) 50.79 (22.55)
Median 0.66 50
Min, max 0.08, 1 0, 100
95% CI 0.46, 0.67 42.04, 59.53
Health state 5 N 35 36
Oﬀ chemotherapy, preprogression
Mean (SD) 0.77 (0.14) 74.56 (16.03)
Median 0.76 77
Min, max 0.52, 1 39, 100
95% CI 0.73, 0.82 69.13, 79.98
Note: 1Utility values range from −0.59 (worse than death)—1 (full health); 2VAS score range-from 0 to 100.
or higher chemotherapy, resp.) had a signiﬁcantly decreased
quality of life compared to HS 5, controlling for number of
sites of metastases. The progressive disease health state (HS
4) had the most negative impact (−24.9) on overall quality
of life when compared with HS 5. The results of the health
state covariates are thus in line with what one would expect.
Thenumberofsitesofmetastasesremainedsigniﬁcantinthe
regression model. As expected, the analyses revealed that the
number of sites of metastases had a negative impact on qual-
ity of life such that each additional site where metastasis was
present would decrease quality of life by an estimated −10.1.
4. Discussion
This study presented utility estimates and HRQoL among
a sample of patients with metastatic soft tissue and bone
sarcoma, excluding GIST. The results indicated the signif-
icant negative impact on disease progression, as patients
with progressive disease consistently reported lower quality
of life, irrespective of which instrument and method was
used. Overall, the results were similar in the mSTS and mBS
subgroups.
Patients on second-line treatment (HS 2) reported
lower utility than patients on ﬁrst-line treatment (HS 1).
Contrary to what one would expect, patients in health
state on 3rd-line or higher chemotherapy (HS 3) had
higher utility than patients on 2nd-line chemotherapy (HS
2), although the diﬀerence is not statistically signiﬁcant.
There are several possible explanations for this. Patients
that move on to receive higher lines of chemotherapy could
potentially be more ﬁt and in better health. Moreover,
patients on higher lines of chemotherapy generally receive
single-agent chemotherapies with less toxicity compared to
multiagent chemotherapy regimens, such as doxorubicin
plus ifosfamide, which are used in earlier lines of therapy.
It should also be noted that the conﬁdence intervals for HS
2 and HS 3 are overlapping as well as the lack of statistical
signiﬁcance comparing these health states, which makes it
diﬃcult to draw any clear conclusions. The uncertainty in
these results is also reﬂected in the analysis of the VAS scores
by health state, where the VAS score declines with higher
lines of chemotherapy. Furthermore, comparing clinically
relevant diﬀerences between HS 2 and HS 3, we see that there
is a clinically relevant negative diﬀerence in utility but “no
change” in the global QoL variable from the EORTC QLQ-
C30 instrument. A larger patient sample could potentially
provide more insight into the exact relationship, but the
diﬀerences in results could also stem from a diﬀerence in
capturing diﬀerences in quality of life between the EQ-5D
and the EORTC QLQ-C30 questionnaires.8 Sarcoma
Table 5: Patients’ QoL based on the QLQ-C30.
Statistic All mSTS mBS General pop.3
Global health status
QoL Mean score (SD) 62.2 (22.8) 62.0 (22.5) 63.3 (24.5) 76.4, (21.8)
Median 66.7 66.7 66.7
Min, max 16.7, 100 16.7, 100 25, 100
95% CI 58, 66.5 57.4, 66.6 51.8, 74.8
Functional scale1
Physical functioning Mean score (SD) 75.0 (19.8) 74.4 (20.3) 78.0 (17.0) 89.4, (17.2)
SD
Min, max 26.7, 100 26.7, 100 46.7, 100
95% CI 71.3, 78.7 70.2, 78.5 70, 86
Role functioning Mean score (SD) 60.6 (33.6) 62.3 (32.9) 52.5 (36.4) 86.5, (24.4)
Min, max 0, 100 0, 100 0, 100
95% CI 54.5, 66.8 55.7, 69 35.5, 69.5
Emotional functioning Mean score (SD) 72.6 (23.2) 72.6 (23.3) 72.9 (23.2) 81.2, (21.1)
Min, max 0, 100 0, 100 8.3, 100
95% CI 68.4, 76.9 67.8, 77.3 62, 83.8
Cognitive functioning Mean score (SD) 83.2 (21.9) 84.2 (19.6) 78.3 (31.1) 88.4, (17.4)
Min, Max 0, 100 0, 100 16.7, 100
95% CI 79.2, 87.2 80.2, 88.2 63.8, 92.9
Social functioning Mean score 65.9 (29.1) 65.8 (29.5) 66.7 (28.1) 90.8, (19.5)
Min, max 0, 100 0, 100 0, 100
95% CI 60.6, 71.3 59.8, 71.8 53.5, 79.8
Symptoms scale2
Fatigue Mean score (SD) 40.1 (28.4) 40.0 (28.5) 40.6 (28.2) 21, (21.7)
Min, max 0, 100 0, 100 0, 100
95% CI 34.9, 45.3 34.3, 45.8 27.3, 53.8
Nausea and vomiting Mean score (SD) 13.8 (20.7) 14.6 (21.3) 10.0 (17.4) 3.3, (10.7)
Min, max 0, 100 0, 100 0, 66.7
95% CI 10, 17.6 10.3, 18.9 1.8, 18.2
Pain Mean score (SD) 27.6 (27.2) 27.6 (27.3) 27.5 (27.2) 18.8, (25.5)
Min, max 0, 100 0, 100 0, 83.3
95% CI 22.6, 32.6 22.1, 33.1 14.8, 40.2
Dyspnoea Mean score (SD) 22.7 (26.2) 22.6 (26.3) 23.3 (26.7) 17.4, (26)
Min, max 0, 100 0, 100 0, 66.7
95% CI 17.9, 27.5 17.2, 27.9 10.8, 35.8
Insomnia Mean score (SD) 28.9 (29.9) 28.4 (29.7) 31.7 (31.5) 17.9, (26.3)
Min, max 0, 100 0, 100 0, 100
95% CI 23.4, 34.5 22.3, 34.5 16.9, 46.4
Appetite loss Mean score (SD) 19.8 (27.1) 21.2 (28.7) 13.3 (16.8) 4.3, (14.7)
Min, max 0, 100 0, 100 0, 33.3
95% CI 14.8, 24.8 15.4, 27 5.5, 21.2
Constipation Mean score (SD) 24.7 (30.5) 26.4 (31.3) 16.7 (25.4) 5.2, (15.7)
Min, max 0, 100 0, 100 0, 66.7
95% CI 19.1, 30.3 20, 32.7 4.8, 28.5
Diarrhea Mean score (SD) 11.8 (22.9) 11.1 (20.3) 15.0 (33.3) 5.2, (15.4)
Min, max 0, 100 0, 66.7 0, 100
95% CI 7.6, 16 7, 15.2 −0.6, 30.6
Financial diﬃculties Mean score (SD) 26.1 (32.4) 25.3 (32.5) 30.0 (32.3) 7, (19.7)
Min, max 0, 100 0, 100 0, 100
95% CI 20.1, 32.1 18.6, 31.9 14.9, 45.1
Note: The following scales had missing values: Global QoL, physical functioning, Insomnia, and ﬁnancial diﬃculties 1a higher score indicates better quality
of life 2a higher score indicates more symptoms; 3General population values, age and sex adjusted for SABINE population [17].Sarcoma 9
Table 6: Clinically relevant diﬀerences between health states.
Health state comparisons
EQ-5D (mean utility) QLQ-C30 (mean global QoL)
Diﬀerence Clinically relevant diﬀerence1 Diﬀerence Clinically relevant diﬀerence2
1st-line CT (HS 1) versus 2nd-line CT (HS 2) 0.08 Positive 7.46 Little change
1st-line CT (HS 1) versus 3rd-line CT (HS 3) −0.05 None 7.84 Little change
2nd-line CT (HS 2) versus 3rd-line CT (HS 3) −0.14 Negative 0.38 No change
Progressive disease (HS 4) versus Oﬀ CT,
preprogression (HS 5)
−0.21 Negative −30.26 Very much change
Note: 10.074 diﬀerence in mean utility, 2“little change” (5–10 points change in the score), a “moderate change” (10–20 points), and “very much change” (>20
points).
Table 7: Multiple linear regression analysis, with health-related quality of life as dependent variable.
Parameter Estimate Standard error t value Pr > |t|
Intercept 90.41 5.95 15.20 <.0001
Health State 1 −9.48 6.29 −1.51 0.1353
Health State 2 −15.92 5.97 −2.67 0.0092
Health State 3 −19.97 7.00 −2.85 0.0054
Health State 4 −24.85 5.68 −4.38 <.0001
Health State 5 0.00 NA NA NA
Number of sites of metastases −10.10 3.13 −3.23 0.0018
Note: Refer to Table 1 for a deﬁnition of the health states. Health state 5 is the reference group.
After having run various speciﬁcations of the regression
model,onlythenumberofsitesofmetastasesandhealthstate
remained signiﬁcant. The regression model included a set of
country indicator variables in the initial speciﬁcation; how-
ever, these variables were removed, because the coeﬃcients
were not statistically signiﬁcant, indicating that there were
no diﬀerences in quality of life between countries.
Comparing the EORTC QLQ-C30 scores reported in
this study with a Swedish study presenting QLQ-C30 values
in the general population indicates that mSTS and mBS
patients have reduced overall quality of life as well as lower
quality of life as measured on both the functional scale
and the symptoms scale [17]. Comparative values for the
general population, age, and sex standardized to the SABINE
population, are displayed in Table 5.
Disease symptoms are common and impacts on mSTS
and mBS patients’ quality of life. Pain is a signiﬁcant
symptom which a majority of patients (54.3%) experience
as mild-to-moderate, and 5.2% of patients as severe in the 3-
itemCancer-RelatedSymptomsQuestionnaire.Thereported
painscore(27.6)ontheEORTCQLQ-C30questionnairewas
also higher than pain in the general population (18.8 [17]).
Respiratory symptoms are also common in mSTS/mBS
patients. 42.2% of patients have mild-to-moderate shortness
of breath. In addition, the dyspnoea score was relatively
high (22.7) compared to that of the general population
(17.4 [17]). Other disease symptoms that were drivers of the
reduction of QoL were fatigue followed by insomnia.
As sarcomas are a heterogeneous group of patients,
only the most common soft tissue histological subtypes
were included in this study (leiomyosarcoma, malignant
ﬁbrous sarcoma, liposarcoma, and synovial sarcoma). Thus,
the prevalence of histological sub-types here is not directly
comparable to population-based studies including all soft
tissue sub-types. In addition, bone sarcoma patients were
included; however, these results were presented separately
due to the fact that QoL, and utility in these patients with
so few patients is highly exploratory.
The study has several strengths. The patient population
is geographically diverse and from a large number of
treatment centres dispersed throughout Europe and North
America. Due to the rarity of the condition, the sample
size of 120 patients was considered relatively large for
a study of metastatic sarcoma (mSTS/mBS) treated with
chemotherapy. The STS types included in this study have a
world incidence rate ranging from 0.1 (synovial sarcoma)
to 0.7 (liposarcoma) per 100,000 per year, while for BS,
the annual incidence rate is 0.3 (Ewing’s sarcoma) and 0.3
(osteosarcoma) [2]. In addition, the identiﬁcation of health
states which are associated with clinically meaningful diﬀer-
ences in health-related quality of life provides quantiﬁcation
of the decrements associated with disease progression and
use of chemotherapy which is important for more accurate
health economic modelling.
The limitations of this study include the possible bias
in selecting healthier patients at the sites to participate in
the study. Subsequent stratiﬁcation of the analysis by health
states (HS) further reduced the sample size within health
states, especially for the mBS subsample. No information on
chemotherapy drug regimen or adverse events was collected.
Anthracycline-basedregimensarelimitedbycumulativetox-
icity (e.g., doxorubicin, doxorubicin plus ifosfamide) while
single-agent regimens have fewer toxicities (e.g., trabectedin
and gemcitabine) but used for longer duration. Comparing
diﬀerent regimens on quality of life would be confounded by
line of therapy, as drugs with cumulative toxicity are often10 Sarcoma
used in early lines, while single-agent regimens with less
toxicity are often used later.
Among the few reported studies of quality-of-life in
patients with metastatic sarcoma, none has presented utility
values. Poveda et al. [11] assessed quality of life in patients
participating in a phase II clinical study with the EORTC
QLQ-C30 questionnaire. Quality of life did not seem to
worsen during therapy. While Poveda et al. enrolled only
patients participating in a clinical trial, our study enrolled
patients in daily clinical practice indicating a better represen-
tative patient sample. In the absence of utility values from
sarcomapatients,Soinietal.[18]usedtheEORTCQLQ-C30
results to predict the utility values by three generic quality of
lifemeasures(EQ-5D,15D,andSF-6D)basedonapublished
regression model [19]. The average expected utilities based
on these instruments were 0.654, 0.736, and 0.668. Despite
thesediﬀerences,thepredictedvaluesaresimilartotheutility
reportedfortheoverallsarcomasamplefromthisstudyusing
the EQ-5D (0.69).
Furthermore, the results of this study will ﬁll the gap
in the literature by providing health utility estimates for
diﬀerent sarcoma health states. As an example of the gap,
an economic model submitted to the UK National Health
Services (NHS) had to use utility values for lung cancer
patients to substitute for sarcoma patients, due to lack of
such data in sarcoma literature. The NHS appraisal com-
mittee questioned the appropriateness of using utility values
from another condition, as a limitation of the submission.
For accurate economic modelling and subsequent resource
allocation decisions, it is critical to collect data on utility
values for the mSTS/mBS population [20].
5. Conclusions
This study demonstrated reduced quality of life in patients
with mSTS and mBS who had a favourable response to
chemotherapy. Quality of life and utility is especially low in
patients with progressive disease. Highest quality of life and
utility is experienced by patients who are oﬀ chemotherapy
and in stable disease. Pain and respiratory symptoms are
important common symptoms. The results from this study
are appropriate for use in economic evaluations of treat-
ments in metastatic soft tissue and bone sarcoma.
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